About STAM-binding protein
STAM-binding protein (STAMBP) is a protein
from Homo sapiens identified by UniProt accession
O95630, 424 residues long.
MolForge cross-references it against 0 known binders and
290 disease associations.
Target properties
| Protein name | STAM-binding protein |
|---|
| UniProt accession | O95630 |
|---|
| Gene | STAMBP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 424 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (290)
Diseases linked to this target (Open Targets).
- microcephaly-capillary malformation syndrome · score 0.80
- neurodegenerative disease · score 0.43
- serum metabolite measurement · score 0.32
- pancreatic adenocarcinoma · score 0.24
- heel bone mineral density · score 0.22
- breast adenocarcinoma · score 0.21
- genetic disorder · score 0.19
- breast carcinoma · score 0.15
- head and neck squamous cell carcinoma · score 0.12
- melanoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O95630-F1 | alphafold | PREDICTED | 84.02 | — |
Amino-acid sequence (424 residues)
MSDHGDVSLP PEDRVRALSQ LGSAVEVNED IPPRRYFRSG VEIIRMASIY SEEGNIEHAF ILYNKYITLF IEKLPKHRDY KSAVIPEKKD TVKKLKEIAF PKAEELKAEL LKRYTKEYTE YNEEKKKEAE ELARNMAIQQ ELEKEKQRVA QQKQQQLEQE QFHAFEEMIR NQELEKERLK IVQEFGKVDP GLGGPLVPDL EKPSLDVFPT LTVSSIQPSD CHTTVRPAKP PVVDRSLKPG ALSNSESIPT IDGLRHVVVP GRLCPQFLQL ASANTARGVE TCGILCGKLM RNEFTITHVL IPKQSAGSDY CNTENEEELF LIQDQQGLIT LGWIHTHPTQ TAFLSSVDLH THCSYQMMLP ESVAIVCSPK FQETGFFKLT DHGLEEISSC RQKGFHPHSK DPPLFCSCSH VTVVDRAVTI TDLR
Explore STAM-binding protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets